Paiva Taylor J, Hallowell Benjamin D, Fischer Staci, Bratberg Jeffrey, St John Kristen, Nitenson Adam Z, Wightman Rachel S
Prescription Drug Monitoring Program (PDMP) Epidemiologist, Center for Health Data and Analysis (CHDA) at RIDOH.
Substance Use Epidemiology Team Lead, CHDA at RIDOH.
R I Med J (2013). 2024 Oct 1;107(10):26-32.
Ketamine is a versatile anesthetic that has been widely used off-label to treat a variety of indications. Esketamine, a derivative of ketamine, is FDA-approved to treat treatment-resistant depression. This report compares statewide prescription ketamine and esketamine trends. Using PDMP data from 2017-2023, prescription and prescriber characteristics, and patient demographics were compared between esketamine and ketamine prescriptions. During this time, ketamine prescriptions, patients, and providers rose 55.8%, 30.6%, and 2.8% since 2017. Esketamine prescriptions increased 1289.4% since 2019. In 2023, ketamine prescriptions were primarily in powder form (98.7%) and paid for out-of-pocket (83.9%), whereas esketamine prescriptions were primarily paid for by insurance (80.2%). The proportion of ketamine prescribed in RI but dispensed out-of-state have increased 22% since 2022 (18% of total dispensations). As more people seek treatment for mental health disorders, ketamine and esketamine prescriptions continue to rise. Understanding ketamine and esketamine use can help mitigate associated adverse events.
氯胺酮是一种用途广泛的麻醉剂，已被广泛用于治疗各种未获批准的适应症。艾司氯胺酮是氯胺酮的衍生物，已获美国食品药品监督管理局（FDA）批准用于治疗难治性抑郁症。本报告比较了全州范围内氯胺酮和艾司氯胺酮的处方趋势。利用2017年至2023年的处方药品监测计划（PDMP）数据，对艾司氯胺酮和氯胺酮处方的处方和开处方者特征以及患者人口统计学进行了比较。在此期间，自2017年以来，氯胺酮处方、患者和开处方者分别增加了55.8%、30.6%和2.8%。自2019年以来，艾司氯胺酮处方增加了1289.4%。2023年，氯胺酮处方主要为粉末形式（98.7%），且自掏腰包支付（83.9%），而艾司氯胺酮处方主要由保险支付（80.2%）。自2022年以来，在罗德岛州开具但在州外配药的氯胺酮比例增加了22%（占总配药量的18%）。随着越来越多的人寻求心理健康障碍的治疗，氯胺酮和艾司氯胺酮的处方量持续上升。了解氯胺酮和艾司氯胺酮的使用情况有助于减轻相关不良事件。
